These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 28522587)

  • 1. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
    Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
    Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
    Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
    Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
    Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
    Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.
    Kerk SA; Finkel KA; Pearson AT; Warner KA; Zhang Z; Nör F; Wagner VP; Vargas PA; Wicha MS; Hurt EM; Hollingsworth RE; Tice DA; Nör JE
    Clin Cancer Res; 2017 May; 23(10):2516-2527. PubMed ID: 27780858
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.
    Sapra P; Damelin M; Dijoseph J; Marquette K; Geles KG; Golas J; Dougher M; Narayanan B; Giannakou A; Khandke K; Dushin R; Ernstoff E; Lucas J; Leal M; Hu G; O'Donnell CJ; Tchistiakova L; Abraham RT; Gerber HP
    Mol Cancer Ther; 2013 Jan; 12(1):38-47. PubMed ID: 23223830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
    Smith RA; Zammit DJ; Damle NK; Usansky H; Reddy SP; Lin JH; Mistry M; Rao NS; Denis LJ; Gupta S
    Mol Cancer Ther; 2021 Aug; 20(8):1327-1337. PubMed ID: 34045226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates.
    Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Gumerov DR; Tang S; Kelleher E; Jones BD; Protopopova M; Qin L; Uttard A; Demady DR; Lowinger TB
    Bioorg Med Chem Lett; 2022 Sep; 72():128876. PubMed ID: 35788036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
    Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
    White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
    MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
    Zammarchi F; Havenith KE; Chivers S; Hogg P; Bertelli F; Tyrer P; Janghra N; Reinert HW; Hartley JA; van Berkel PH
    Mol Cancer Ther; 2022 Apr; 21(4):582-593. PubMed ID: 35086955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography.
    Giddabasappa A; Gupta VR; Norberg R; Gupta P; Spilker ME; Wentland J; Rago B; Eswaraka J; Leal M; Sapra P
    Mol Cancer Ther; 2016 Oct; 15(10):2530-2540. PubMed ID: 27466353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Therapeutic Window in
    Zhong H; Chen C; Tammali R; Breen S; Zhang J; Fazenbaker C; Kennedy M; Conway J; Higgs BW; Holoweckyj N; Raja R; Harper J; Pierce AJ; Herbst R; Tice DA
    Mol Cancer Ther; 2019 Jan; 18(1):89-99. PubMed ID: 30352801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.
    Boghaert ER; Sridharan L; Khandke KM; Armellino D; Ryan MG; Myers K; Harrop R; Kunz A; Hamann PR; Marquette K; Dougher M; DiJoseph JF; Damle NK
    Int J Oncol; 2008 Jan; 32(1):221-34. PubMed ID: 18097562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
    Gregson SJ; Pugh K; Patel N; Afif-Rider S; Vijayakrishnan B; Santos K; Riedl J; Hutchinson I; Kang GD; Chooi KP; Beard R; Adams L; Barry CS; Ball K; Masterson LA; McFarlane M; Hartley JA; Howard PW
    Mol Cancer Ther; 2022 Sep; 21(9):1439-1448. PubMed ID: 35793464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
    Gregson SJ; Masterson LA; Wei B; Pillow TH; Spencer SD; Kang GD; Yu SF; Raab H; Lau J; Li G; Lewis Phillips GD; Gunzner-Toste J; Safina BS; Ohri R; Darwish M; Kozak KR; Dela Cruz-Chuh J; Polson A; Flygare JA; Howard PW
    J Med Chem; 2017 Dec; 60(23):9490-9507. PubMed ID: 29112410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.